Market Overview:
The global preimplantation genetics diagnosis (PGD) market is expected to grow at a CAGR of 10.5% from 2018 to 2030. The growth in the PGD market can be attributed to the increasing incidence of genetic disorders, technological advancements in PGD procedures, and rising demand for PGD services from hospitals and clinics. Based on type, the global PGD market is segmented into gender selection, chromosomal abnormalities, single gene disorders, HLA typing, aneuploidy, X-linked diseases, and others. The chromosomal abnormalities segment is expected to account for the largest share of the global PGD market in 2018. This segment is further divided into Down syndrome screening & diagnosis; Turner syndrome screening & diagnosis; Klinefelter syndrome screening & diagnosis; Edwards syndrome screening & diagnosis; Patau Syndrome screening & diagnosis; and other chromosomal abnormalities. The Down syndrome screening &diagnosis subsegment accounted for the largest share of this segment in 2017 owing to its high prevalence rate across all regions worldwide. Based on application type, hospitals accounted for the majority share of the global PGD market in 2017 followed by clinics.
Product Definition:
Preimplantation genetics diagnosis (PGD) is a technique used in assisted reproduction to help identify potential genetic disorders in embryos before implantation. PGD can be used to detect single-gene defects and chromosomal abnormalities. The use of PGD has the potential to improve the chances for a successful pregnancy while reducing the risk of passing on a genetic disorder.
Gender Selection:
Introduction of gender selection in preimplantation genetic diagnosis (PGD) has helped to increase the success rate of in vitro fertilization (IVF) treatment procedures. PGD is used for identifying an embryo with a compatible chromosomal makeup for successful IVF pregnancy. The presence of gender selection tools aids the clinicians to choose an appropriate embryo for implantation, thus improving the chances of pregnancy.
Chromosomal Abnormalities:
Chromosomal abnormalities are the structural or functional abnormalities in the DNA and/or the RNA of Chromatids (crossover, non-crossover). These abnormal genes may lead to disease conditions if they are present in a fertile individual. The most common chromosomal diseases include Down’s syndrome, Edward’s syndrome, Patau syndrome and Turner syndrome. PGD is used for detecting these genetic disorders during early stages of embryo development before implantation.
Application Insights:
The others segment held the largest share of over 70.0% in 2017. This is due to the increasing use of preimplantation genetic diagnosis for embryo screening and follow-up testing for chromosomal abnormalities, aneuploidy, and X-linked diseases among other reasons. Chromosomal abnormalities segment is expected to be fastest growing application owing to its high incidence rate globally coupled with rising adoption by assisted reproductive technology clinics and hospitals across the world.
Single gene disorders are also expected to grow at a significant pace during the forecast period as these conditions are highly prevalent among individuals living in families affected by them, which acts as a strong indication that this procedure should be offered on a routine basis rather than being limited only to cases where there is no family history of similar conditions or when there are symptoms present that cannot be detected through blood tests alone such as late onset disease or severe disability caused by premature birth.
Regional Analysis:
Europe dominated the global preimplantation genetics diagnosis market in 2017. This can be attributed to the presence of a large number of fertility clinics that offer PGD procedures, high adoption rate of IVF technology and availability of several government support schemes for infertile couples. Asia Pacific is expected to grow at a lucrative CAGR during the forecast period due to increasing infertility rates, awareness about available treatment options and government initiatives for improving healthcare infrastructure in this region. Moreover, rising disposable income levels will boost demand for PGD services over the forecast period.
Growth Factors:
- Increasing demand for PGD services due to increasing incidence of genetic disorders and chromosomal abnormalities.
- Growing awareness about the benefits of PGD among couples planning to have a baby.
- Rising number of fertility clinics offering PGD services worldwide.
- Technological advancements in PGD procedures that are making the process more efficient and accurate.
- Increase in funding for research on preimplantation genetics and its applications
Scope Of The Report
Report Attributes
Report Details
Report Title
Preimplantation Genetics Diagnosis (PGD) Market Research Report
By Type
Gender Selection, Chromosomal Abnormalities, Single Gene Disorders, HLA Typing, Aneuploidy, X-Linked Diseases, Others
By Application
Hospitals, Clinics, Others
By Companies
Abbott Laboratories, Natera, Inc, PerkinElmer, Illumina, F. Hoffmann-La Roche, Thermo Fisher Scientific, Laboratory Corporation of America Holdings, Agilent Technologies, Quest Diagnostics Incorporated, Cooper Surgical, Beijing Genomics Institute (BGI), Genea Limited
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
195
Number of Tables & Figures
137
Customization Available
Yes, the report can be customized as per your need.
Global Preimplantation Genetics Diagnosis (PGD) Market Report Segments:
The global Preimplantation Genetics Diagnosis (PGD) market is segmented on the basis of:
Types
Gender Selection, Chromosomal Abnormalities, Single Gene Disorders, HLA Typing, Aneuploidy, X-Linked Diseases, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott Laboratories
- Natera, Inc
- PerkinElmer
- Illumina
- F. Hoffmann-La Roche
- Thermo Fisher Scientific
- Laboratory Corporation of America Holdings
- Agilent Technologies
- Quest Diagnostics Incorporated
- Cooper Surgical
- Beijing Genomics Institute (BGI)
- Genea Limited
Highlights of The Preimplantation Genetics Diagnosis (PGD) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Gender Selection
- Chromosomal Abnormalities
- Single Gene Disorders
- HLA Typing
- Aneuploidy
- X-Linked Diseases
- Others
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Preimplantation Genetics Diagnosis (PGD) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Preimplantation Genetic Diagnosis (PGD) is a process by which embryos that may have genetic disorders can be screened for abnormalities before they are implanted into the uterus. If an embryo has a disorder, it can be eliminated from the pregnancy.
Some of the major players in the preimplantation genetics diagnosis (pgd) market are Abbott Laboratories, Natera, Inc, PerkinElmer, Illumina, F. Hoffmann-La Roche, Thermo Fisher Scientific, Laboratory Corporation of America Holdings, Agilent Technologies, Quest Diagnostics Incorporated, Cooper Surgical, Beijing Genomics Institute (BGI), Genea Limited.
The preimplantation genetics diagnosis (pgd) market is expected to register a CAGR of 10.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Preimplantation Genetics Diagnosis (PGD) Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Preimplantation Genetics Diagnosis (PGD) Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Preimplantation Genetics Diagnosis (PGD) Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Preimplantation Genetics Diagnosis (PGD) Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Preimplantation Genetics Diagnosis (PGD) Market Size & Forecast, 2018-2028 4.5.1 Preimplantation Genetics Diagnosis (PGD) Market Size and Y-o-Y Growth 4.5.2 Preimplantation Genetics Diagnosis (PGD) Market Absolute $ Opportunity
Chapter 5 Global Preimplantation Genetics Diagnosis (PGD) Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Preimplantation Genetics Diagnosis (PGD) Market Size Forecast by Type
5.2.1 Gender Selection
5.2.2 Chromosomal Abnormalities
5.2.3 Single Gene Disorders
5.2.4 HLA Typing
5.2.5 Aneuploidy
5.2.6 X-Linked Diseases
5.2.7 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Preimplantation Genetics Diagnosis (PGD) Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Preimplantation Genetics Diagnosis (PGD) Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Preimplantation Genetics Diagnosis (PGD) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Preimplantation Genetics Diagnosis (PGD) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Preimplantation Genetics Diagnosis (PGD) Analysis and Forecast
9.1 Introduction
9.2 North America Preimplantation Genetics Diagnosis (PGD) Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Preimplantation Genetics Diagnosis (PGD) Market Size Forecast by Type
9.6.1 Gender Selection
9.6.2 Chromosomal Abnormalities
9.6.3 Single Gene Disorders
9.6.4 HLA Typing
9.6.5 Aneuploidy
9.6.6 X-Linked Diseases
9.6.7 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Preimplantation Genetics Diagnosis (PGD) Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Preimplantation Genetics Diagnosis (PGD) Analysis and Forecast
10.1 Introduction
10.2 Europe Preimplantation Genetics Diagnosis (PGD) Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Preimplantation Genetics Diagnosis (PGD) Market Size Forecast by Type
10.6.1 Gender Selection
10.6.2 Chromosomal Abnormalities
10.6.3 Single Gene Disorders
10.6.4 HLA Typing
10.6.5 Aneuploidy
10.6.6 X-Linked Diseases
10.6.7 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Preimplantation Genetics Diagnosis (PGD) Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Preimplantation Genetics Diagnosis (PGD) Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Preimplantation Genetics Diagnosis (PGD) Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Preimplantation Genetics Diagnosis (PGD) Market Size Forecast by Type
11.6.1 Gender Selection
11.6.2 Chromosomal Abnormalities
11.6.3 Single Gene Disorders
11.6.4 HLA Typing
11.6.5 Aneuploidy
11.6.6 X-Linked Diseases
11.6.7 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Preimplantation Genetics Diagnosis (PGD) Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Preimplantation Genetics Diagnosis (PGD) Analysis and Forecast
12.1 Introduction
12.2 Latin America Preimplantation Genetics Diagnosis (PGD) Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Preimplantation Genetics Diagnosis (PGD) Market Size Forecast by Type
12.6.1 Gender Selection
12.6.2 Chromosomal Abnormalities
12.6.3 Single Gene Disorders
12.6.4 HLA Typing
12.6.5 Aneuploidy
12.6.6 X-Linked Diseases
12.6.7 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Preimplantation Genetics Diagnosis (PGD) Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Preimplantation Genetics Diagnosis (PGD) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Preimplantation Genetics Diagnosis (PGD) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Preimplantation Genetics Diagnosis (PGD) Market Size Forecast by Type
13.6.1 Gender Selection
13.6.2 Chromosomal Abnormalities
13.6.3 Single Gene Disorders
13.6.4 HLA Typing
13.6.5 Aneuploidy
13.6.6 X-Linked Diseases
13.6.7 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Preimplantation Genetics Diagnosis (PGD) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Preimplantation Genetics Diagnosis (PGD) Market: Competitive Dashboard
14.2 Global Preimplantation Genetics Diagnosis (PGD) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abbott Laboratories
14.3.2 Natera, Inc
14.3.3 PerkinElmer
14.3.4 Illumina
14.3.5 F. Hoffmann-La Roche
14.3.6 Thermo Fisher Scientific
14.3.7 Laboratory Corporation of America Holdings
14.3.8 Agilent Technologies
14.3.9 Quest Diagnostics Incorporated
14.3.10 Cooper Surgical
14.3.11 Beijing Genomics Institute (BGI)
14.3.12 Genea Limited